Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Jonathan Goldman, M.D.
Jonathan Goldman, M.D.

Specialty:

Hematology/Oncology

General Information:

Gender:
Male
Language(s):
English, Spanish

Affiliation(s):

HS Clinical Instructor, Department of Medicine, Hematology/Oncology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
St. John's Medical Center

Education:

Fellowship:
Hematology-Oncology, UCLA School of Medicine, 2005 - 2008
Residency:
UC San Francisco School of Medicine, 2002 - 2004
Internship:
Internal Medicine, UC San Francisco School of Medicine, 2001 - 2002
Medical Degree:
M.D., Stanford University School of Medicine, 1996

Certification(s):

Medical Board Certification(s):
Hematology, American Board of Internal Medicine, 2008
Medical Oncology, American Board of Internal Medicine, 2008
Internal Medicine, American Board of Internal Medicine, 2004

Contact Information:

Phone:
(310) 829-5471
Email:

Practice Information:

Clinical Interest(s):
Early Drug Development
Hematology
Lung Cancer
Solid Oncology

Scientific Interest(s):

Dr. Jonathan Goldman focuses on lung cancer research and early drug development.

Selected Cancer-Related Publications:

Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Submitted for review.

Goldman JW, Garon EB. Targeting MEK for the treatment of non-small cell lung cancer: a review from the 12th annual targeted therapies of treatment of lung cancer. Journal of Thoracic Oncology, 2012.

Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.

Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar;127(3):343-5.

O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 1991 Aug;3(8):233-40.